Riskpilot← Back to searchSign inGet full accessLeira Therapeutics AB
ABActiveOrg 5591992853Ledungsvägen 21 BActivities of psychologists and psychotherapists, except medical doctors · NACE 8693Est. 20190 employees
Revenue 2025
SEK 211K
-5% vs 2024
EBITDA margin
80.1%
+774% vs 2024
Equity ratio
92.8%
Financial strength
Net profit 2025
SEK 155K
+671% vs 2024
| Revenue | SEK 211K | -5% |
| EBITDA | SEK 169K | +774% |
| Net profit | SEK 155K | +671% |
| Total assets | SEK 401K | +29% |
| Equity | SEK 372K | +72% |
| Employees | 0 | — |
Legal name
Leira Therapeutics AB
Org number
5591992853
Legal form
Aktiebolag
NACE code
8693 · Activities of psychologists and psychotherapists, except medical doctors
Founded
19 mars 2019
Share capital
SEK 50 000
Employees
0
VAT registered
Yes
Audit selected
No
Last report
2025-12-31
Financial year
January – December
Signatory rights
Firman tecknas av styrelsen Firman tecknas var för sig av ledamoten suppleanten
Company purpose
Bolaget skall bedriva vård, forskning, utveckling, marknadsföring och försäljning av psykologisk behandling, såväl fysisk som i digital form. Bolaget ska därtill investera och förvalta aktier, äga och förvalta fast egendom samt idka därmed förenlig verksamhet.
Address
Ledungsvägen 21 B
Email
berkeh.nasri@gmail.com
Risika for professionals
Risika provides regulated workflow tools for finance, procurement and compliance teams that need monitoring, alerts and an API.
| Item | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Revenue | 2 273 | 203 | 321 | 223 | 211 |
| Staff expenses | — | −228 | −244 | −101 | — |
| EBITDA | 28 | −128 | 7 | 19 | 169 |
| Depreciation & amort. | −0 | — | — | — | −0 |
| EBIT | 28 | −128 | 7 | 19 | 169 |
| Net financials | — | −0 | −0 | 1 | 1 |
| Profit before tax | 28 | −128 | 7 | 20 | 170 |
| Tax | −7 | 0 | — | — | −15 |
| Net profit | 21 | −128 | 7 | 20 | 155 |
| Item | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Total assets | 497 | 253 | 228 | 311 | 401 |
| Equity | 318 | 190 | 197 | 217 | 372 |
| Long-term debt | 0 | — | — | — | 0 |
| Short-term debt | 179 | 63 | 32 | 94 | 30 |
| Total debt | 179 | 63 | 32 | 94 | 30 |
EBITDA margin
80.1%
This company
15.8%
Market median
+407% vs market
20212025
Equity ratio
92.8%
This company
38.2%
Market median
+143% vs market
20212025
Return on equity
41.7%
This company
18.4%
Market median
+127% vs market
20212025
Net profit margin
73.5%
This company
8.1%
Market median
+807% vs market
20212025
Asset turnover
0.53×
This company
1.12×
Market median
-53% vs market
20212025
Debt / equity
0.08×
This company
0.62×
Market median
+87% vs market
20212025
- Annual report 2025Filed via Bolagsverket / SCB · Period 2025-01-01 – 2025-12-31
- Annual report 2024Filed via Bolagsverket / SCB · Period 2024-01-01 – 2024-12-31
- Annual report 2023Filed via Bolagsverket / SCB · Period 2023-01-01 – 2023-12-31
- Annual report 2022Filed via Bolagsverket / SCB · Period 2022-01-01 – 2022-12-31
- Annual report 2021Filed via Bolagsverket / SCB · Period 2021-01-01 – 2021-12-31
| Name | Role | Member since |
|---|---|---|
| Current (1) | ||
BN Chief Executive Officer | Chief Executive Officer | 2022 |
| Name | Role | Member since |
|---|---|---|
| Current (1) | ||
| Deputy Board Member | 2022 | |
| Former (1) | ||
| Chairman | 2022 – 2025 | |
| Shareholder | Type | Ownership | Votes | Since |
|---|---|---|---|---|
| Company | 65% | 65% | 2023 |
Beneficial ownership (UBO) data access is restricted in Denmark as of September 2025 per the EU 6th AML Directive. Learn more.
Aryèle Holding AB
Leira Therapeutics AB Board members of Leira Therapeutics AB also hold positions in 0 other companies.
| Person | Role here | Other companies |
|---|---|---|
| Berkeh Nasri | Chief Executive Officer | 0 companies |
| Fredrik Göran Wetterhall | Chairman | 0 companies |
| Keyvan Kevin Bashiri | Deputy Board Member | 0 companies |